Current Edition

Adamas

Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff

As Supernus’ top drug inches toward the patent cliff, the central nervous system-focused drugmaker has struck an M&A deal to quickly expand its portfolio of …

Continue Reading →